3 completed, 2 active not recruiting, 1 terminated. 3 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow caficrestat: new trials by email Literature Review of caficrestat trials Research Report on caficrestat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA) NACA - Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain | Phase 2 | Active not recruiting | Arctic Therapeutics | 15 | 2024-04-03 | 2026-07-21 |
| Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer Eribulin Mesylate, Grapiprant - Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2021-12-21 | 2025-06-13 |
| Cardiovascular Effects of COVID-19 AT-001 - COVID-19 | Phase 2 | Completed | NYU Langone Health | 81 | 2020-04-08 | 2021-09-16 |
| Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy AT-001, Placebo - Diabetic Cardiomyopathies | Phase 3 | Active not recruiting | Applied Therapeutics, Inc. | 675 | 2019-09-20 | 2022-12-08 |
| AT-001 for Long-term Preservation of Brain Health in Aging AT-001, Placebo - Oxidative Stress | Not applicable | Completed | University of Kentucky | 95 | 2016-05-01 | 2019-08-20 |
| Safety and Tolerability of Antioxidant (AT-001)for Reducing Brain Oxidative Stress AT-001, Placebo - Oxidative Stress | Phase 1 | Completed | Alltech Life Sciences Inc. | 24 | 2012-03-01 | 2014-01-23 |
COVID-19 (1) · Cerebral Amyloid Angiopathy, Familial (1) · Cerebral Hemorrhage (1) · Dementia (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Cardiomyopathies (1) · Inflammatory Breast Neoplasms (1) · Intracranial Hemorrhages (1)
Alltech Life Sciences Inc. (1) · Applied Therapeutics, Inc. (1) · Arctic Therapeutics (1) · M.D. Anderson Cancer Center (1) · NYU Langone Health (1) · University of Kentucky (1)
United States (5) · Australia (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Hong Kong (1) · Iceland (1) · Poland (1) · Spain (1) · United Kingdom (1)
Gregory A Jicha, MD, PhD (1) · Gregory A. Jicha, MD, PhD (1) · James L Januzzi, MD (1) · Richard R Murphy, MD (1) · Ronan Power, PhD (1) · Ronan Powers, PhD (1) · Sadia Saleem (1) · Stuart Katz, MD (1)
PMID 38302936, PMID 38597864, PMID 38986667, PMID 39095808, PMID 39806375, PMID 39882614, PMID 40315802, PMID 40338768, PMID 42538062
2023 (1)